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Randomised controlled trial of dual blockade of
renin›angiotensin system in patients with hypertension,
microalbuminuria, and non›insulin dependent diabetes: the
candesartan and lisinopril microalbuminuria (CALM) study
Carl Erik Mogensen, Steen Neldam, Ilkka Tikkanen, Shmuel Oren, Reuven Viskoper,
Richard W Watts, Mark E Cooper for the CALM study group
Abstract
Objectives To assess and compare the effects of
candesartan or lisinopril, or both, on blood pressure
and urinary albumin excretion in patients with
microalbuminuria, hypertension, and type 2 diabetes.
Design Prospective, randomised, parallel group,
double blind study with four week placebo run in
period and 12 weeks’ monotherapy with candesartan
or lisinopril followed by 12 weeks’ monotherapy or
combination treatment.
Setting Tertiary hospitals and primary care centres in
four countries (37 centres).
Participants 199 patients aged 30›75 years.
Interventions Candesartan 16 mg once daily,
lisinopril 20 mg once daily.
Main outcome measures Blood pressure and urinary
albumin:creatinine ratio.
Results At 12 weeks mean (95% confidence interval)
reductions in diastolic blood pressure were 9.5 mm
Hg (7.7 mm Hg to 11.2 mm Hg, P < 0.001) and 9.7
mm Hg (7.9 mm Hg to 11.5 mm Hg, P < 0.001),
respectively, and in urinary albumin:creatinine ratio
were 30% (15% to 42%, P < 0.001) and 46% (35% to
56%, P < 0.001) for candesartan and lisinopril,
respectively. At 24 weeks the mean reduction in
diastolic blood pressure with combination treatment
(16.3 mm Hg, 13.6 mm Hg to 18.9 mm Hg, P < 0.001)
was significantly greater than that with candesartan
(10.4 mm Hg, 7.7 mm Hg to 13.1 mm Hg, P < 0.001)
or lisinopril (mean 10.7 mm Hg, 8.0 mm Hg to 13.5
mm Hg, P < 0.001). Furthermore, the reduction in
urinary albumin:creatinine ratio with combination
treatment (50%, 36% to 61%, P < 0.001) was greater
than with candesartan (24%, 0% to 43%, P = 0.05) and
lisinopril (39%, 20% to 54%, P < 0.001). All treatments
were generally well tolerated.
Conclusion Candesartan 16 mg once daily is as
effective as lisinopril 20 mg once daily in reducing
blood pressure and microalbuminuria in hypertensive
patients with type 2 diabetes. Combination treatment
is well tolerated and more effective in reducing blood
pressure.
Introduction
The role of inhibition of the renin›angiotensin system
in preventing microvascular complications, particu›
larly nephropathy, in patients with daibetes has been
clearly shown.1–3 In many people with evidence of dia›
betic renal disease, however, angiotensin converting
enzyme (ACE) inhibitors alone fail to achieve blood
pressure targets. There is increasing evidence that
angiotensin II (AII), the effector molecule of the renin›
angiotensin system, can be generated not only by the
ACE enzyme but also by other pathways including
chymase.4–6 The advent of angiotensin II type 1 (AT1)
receptor blockers provides an alternative approach to
blocking the renin›angiotensin system. These antago›
nists, however, block only one subtype of the
angiotensin II receptor, the type 1 subtype, and in con›
trast with ACE inhibitors do not promote accumula›
tion of vasodilatory substances such as bradykinin. In
normal subjects, this combination has been shown to
be effective at decreasing blood pressure.4 7 8 We
compared the effects of candesartan9 (a type 1 receptor
blocker) and lisinopril10 on blood pressure and urinary
albumin excretion and evaluated the effects of the
combination of both drugs in patients with hyper›
tension, microalbuminuria, and type 2 diabetes.
Participants and methods
This study has been described according to the CON›
SORT guidelines for the presentation of clinical trials.11
This randomised, double blind, double dummy study
was performed in 37 centres (12 in Australia, nine in
Denmark, four in Finland, and 12 in Israel) in patients
with type 2 diabetes who were aged between 30 and 75
years old and had previously diagnosed hypertension
and microalbuminuria.
We included patients if the urinary albumin:creati›
nine ratio was 2.5›25 mg/mmol and the diastolic blood
pressure was 90›110 mm Hg after two and four weeks
of placebo treatment, respectively. Exclusion criteria
were: body mass index >40 kg/m2, systolic blood pres›
sure > 200 mm Hg, non›diabetic cause of secondary
hypertension, cardiovascular event in the past six
months, serum creatinine concentration >130 ×6d
mol/l in women and >150 ×6d mol/l in men, serum
potassium concentration > 5.5 mmol/l, glycated
haemoglobin concentration (HbA1c) > 10%, preg›
nancy or potential pregnancy, and breast feeding.
After four weeks of placebo treatment, eligible
patients were randomised to four treatment groups.
Figure 1 gives details of the randomisastion and treat›
ment. Consequently, half the patients received cande›
sartan and half received lisinopril for the first 12 weeks.
From 12 to 24 weeks, one third of the patients received
candesartan alone, one third lisinopril alone, and one
third the combination, unless patients had diastolic
blood pressure below 80 mm Hg at 12 weeks.
The patients attended the clinic for a total of nine
study visits: at four and two weeks before randomisa›
tion, at randomisation (week 0), and at 1, 6, 12, 13, 18,
and 24 weeks after randomisation. At each visit blood
pressure was measured in the morning after five
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administration, with an automatic device (Omron
HEM›705 CP, Omron Electronics, Tokyo, Japan).
Sitting blood pressure was measured three times with
an interval of about two minutes, and the mean was
calculated. The standing blood pressure was measured
once after one minute of standing.
Microalbuminuria was determined two weeks
before randomisation and at weeks 0, 12, and 24 by cal›
culation of the urinary albumin:creatinine ratio.3 For
each determination the patients brought early morning
voided urine samples from two consecutive days. Albu›
min concentration was measured by immunoturbidim›
etry, and creatinine concentration was measured by
autoanalyser. Creatinine clearance was calculated with
the Cockroft›Gault formula ((140 − age)×body weight
(kg)×K/serum creatinine (ìmol/l). K (constant) was
1.25 for men and 1.03 for women. Haemoglobin A1c
was measured by high performance liquid chromatog›
raphy at weeks 0, 12, and 24. Clinical chemistry, haema›
tology, and urinalysis were performed at weeks 0, 12,
and 24 with standard methods. Serum creatinine and
potassium concentrations were also measured at weeks
1 and 13. The ACE genotype was determined as previ›
ously described.12 Tolerability was assessed by using
spontaneously reported adverse events, recorded in
response to an open question or observed by the
investigator at each visit.
The study was performed in accordance with the
principles stated in the Declaration of Helsinki and
approval was obtained from each institution’s ethics
committee. All patients gave their informed consent
before being included in the study.
Statistical methods
The assumed standard deviation for the change in uri›
nary albumin excretion was 1.1 on a logged scale. This
would allow estimation of the ratio of the expected
medians with a relative error of at most 33% with a
probability of 95%. As we used the mean of two early
morning measurements we predicted that the variabil›
ity between indiviuals would be reduced. In conse›
quence, the observed relative error could be expected
to be smaller than assumed. We therefore calculated
that we needed about 220 patients.
For all treatments we analysed the changes from
baseline (randomisation) to 12 and 24 weeks in blood
pressure, urinary albumin:creatinine ratio, and creati›
nine clearence with a linear model for analysis of co›
variance with factors for treatment, centre, and
interaction between them and baseline value as a co›
variate. For urinary albumin:creatinine ratio the changes
in diastolic blood pressure and body weight were also
used as covariates. The urinary albumin: creatinine ratio
was analysed after logarithmic transformation. Differ›
ences between treatments were estimated from the fitted
model (analysis of covariance). The results for urinary
albumin:creatinine ratio are presented as estimates of
the true treatment geometric means and as estimates of
the ratios of the true treatment geometric means, with
their 95% confidence intervals and corresponding P
values. All analyses were based on intention to treat
(defined as all patients who took at least one dose and
had efficacy data available after randomisation), with the
last value carried forward for missing values.
Results
As one randomised patient never took the study
medication and for one other patient we had no
efficacy data after randomisation there was a total of
197 evaluable patients.
Effects on blood pressure and urinary albumin
excretion
After 12 weeks’ treatment
Table 1 shows that there were no significant differences
in baseline characteristics for the candesartan (n = 99)
Table 1 Baseline characteristics of patients with hypertension,
microalbuminuria, and type 2 diabetes followed from baseline to
12 weeks. Figures are means (SD) unless stated otherwise
Candesartan Lisinopril
No of patients 99 98
Age (years) 59.7 (9.9) 60.0 (8.5)
No of men 66/33 62/36
Body mass index (kg/m2) 30.7 (4.3) 29.8 (3.8)
Duration of hypertension (years) 8.3 (8.8) 9.0 (8.9)
Duration of diabetes (years) 9.8 (7.5) 8.4 (7.3)
Systolic blood pressure (mm Hg) 162.7 (17.7) 162.6 (17.6)
Diastolic blood pressure (mm Hg) 96.0 (6.2) 95.7 (6.2)
Urinary albumin:creatinine ratio (mg/mmol)* 5.9 (1.1) 6.6 (1.1)
Serum creatinine (ìmol/l) 85.8 (18.9) 85.0 (16.8)
Creatinine clearance (ml/min) 103.1 (37.7) 96.0 (28.7)
Haemoglobin A1C (%) 7.6 (1.2) 7.6 (1.6)
ACE genotype (DD/ID/II/not known) 28/45/14/12 32/41/20/5
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Fig 1 Distribution of participants in study. Doses were: candesartan
16 mg once daily, lisinopril 20 mg once daily, or their combination
Table 2 Adjusted* mean reductions in blood pressure and urinary albumin:creatinine ratio from baseline to 12 weeks in patients with
hypertension, microalbuminuria, and type 2 diabetes
Candesartan Lisinopril Adjusted mean difference between treatments
Sitting diastolic blood pressure (mm Hg) 9.5 (7.7 to 11.2); P<0.001 9.7 (7.9 to 11.5); P<0.001 0.2 (−2.3 to 2.7); P >0.20
Sitting systolic blood pressure (mm Hg) 12.4 (9.1 to 15.8); P<0.001 15.7 (12.2 to 19.2); P<0.001 3.3 (−1.5 to 8.2); P=0.18
Urinary albumin:creatinine ratio (%) 30 (15 to 42); P<0.001 46 (35 to 56); P<0.001 30 (1 to 71); P=0.058†
*Adjusted for centre, treatment, baseline value, weight, and change in diastolic blood pressure.
†Relative reduction.
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and lisinopril (n = 98) groups. Eighteen in the
candesartan group and 27 in the lisinopril group also
received hydrochlorothiazide 12.5 mg once daily. In
both groups about 80% of the patients were taking oral
antidiabetic drugs and 20% were taking insulin. Both
drugs reduced blood pressure and urinary albumin›
:creatinine ratio significantly from baseline to 12 weeks.
Table 2 summarises the results.
After 24 weeks treatment
Table 3 show the baseline characteristics of the three
groups followed to 24 weeks. Patients who were
withdrawn from the study at the 12 week visit, mostly
because their diastolic blood pressure was below 80
mm Hg, are not included in the 24 week analysis. After
24 weeks we had data for 49 in the candesartan group,
46 in the lisinopril group, and 49 in the combination
group. A few patients in each treatment group also
received hydrochlorothiazide 12.5 mg once daily (can›
desartan n = 7, lisinopril n = 6, combination n = 6).
Table 4 shows that all three treatments reduced
both blood pressure and urinary albumin:creatinine
ratio from baseline to 24 weeks, with the combination
being the most effective. There was no significant
difference in the reductions in systolic blood pressure
observed after treatment with candesartan or lisinopril.
The reductions in standing blood pressures were simi›
lar to the reductions in seated blood pressures.
Figure 2 shows mean systolic and diastolic blood
pressure in the three treatment groups at different time
points. In the group of patients who received the com›
bination treatment after 12 weeks there was a measur›
able further reduction in both systolic and diastolic
blood pressure. There was no significant influence of
ACE genotype on response of either albuminuria or
blood pressure to any of the treatments studied.
Tolerability
All treatment regimens were generally well tolerated.
The most common adverse events during any of the
treatment regimens were respiratory infection, cough,
and headache, which occurred in less than 10% of the
patients. Only 14 out of 197 randomised patients
stopped treatment because of adverse events during
the 24 week double blind period. Five patients discon›
tinued because of dizziness or feeling weak, or both
(two patients on candesartan, two on lisinopril, and one
on the combination), while three patients discontinued
because of cough (all treated with lisinopril). Other
adverse events that caused patients to stop treatment
occurred in single patients only.
There were no clear changes in mean values for
haemoglobin A1c or any routine laboratory variables
from baseline to 12 or 24 weeks in any of the treatment
groups. Slight increases of doubtful clinical significance
Table 3 Baseline characteristics of patients with hypertension,
microalbuminuria, and type 2 diabetes followed from baseline to




No of patients* 66 64 67
Age (years) 59.7 (9.9) 59.9 (9.0) 59.8 (8.7)
No of men 48 43 37
Body mass index (kg/m2) 31.0 (4.2) 29.6 (3.7) 30.2 (4.2)
Duration of hypertension
(years)
8.3 (8.9) 7.9 (8.1) 9.7 (9.3)
Duration of diabetes (years) 10.0 (7.7) 8.3 (7.0) 9.1 (7.7)
Systolic blood pressure
(mm Hg)
163.3 (19.0) 163.0 (17.2) 161.7 (16.7)
Diastolic blood pressure
(mm Hg)
96.6 (6.9) 96.2 (5.2) 94.8 (6.4)
Urinary albumin:creatinine ratio
(mg/mmol)†
7.2 (1.1) 5.9 (1.2) 5.6 (1.1)
Serum creatinine (ìmol/l) 88.3 (18.5) 85.6 (16.7) 82.4 (18.1)
Creatinine clearance (ml/min) 103.5 (38.4) 96.8 (28.9) 98.4 (32.9)




*Two patients lost to follow up (see text for details).
†Geometric mean (tolerance factors).
Table 4 Adjusted* mean reduction in blood pressure and urinary albumin:creatinine ratio from baseline to 24 weeks in patients with hypertension,
microalbuminuria, and type 2 diabetes
Candestartan Lisinopril Combination
Adjusted mean difference
Combination v candestartan Combination v lisinopril
Sitting diastolic blood pressure (mm Hg) 10.4 (7.7 to 13.1); P<0.001 10.7 (8.0 to 13.5); P<0.001 16.3 (13.6 to 18.9); P<0.001 5.9 (2.1 to 9.7); P=0.003 5.6 (1.7 to 9.4); P=0.005
Sitting systolic blood pressure (mm Hg) 14.1 (8.9 to 19.2); P<0.001 16.7 (11.4 to 21.9); P<0.001 25.3 (20.3 to 30.3); P<0.001 11.2 (4.1 to 18.4); P=0.002 8.6 (1.4 to 15.9); P=0.02
Urinary albumin:creatinine ratio (%) 24 (0 to 43); P=0.05 39 (20 to 54); P<0.001 50 (36 to 61); P<0.001 34 (3 to 55); P=0.04 18 (−20 to 44); P>0.20

































Fig 2 Mean (SE) seated systolic and diastolic blood pressure in
patients with type 2 diabetes mellitus, hypertension, and
microalbuminuria before and during treatment with candesartan 16 mg
once daily (n=49), lisinopril 20 mg once daily (n=46), or combination
of candesartan and lisinopril (n=49). Combination group received
monotherapy with either candesartan or lisinopril for first 12 weeks
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were observed at 24 weeks in serum concentrations of
creatinine (8.1×6d mol/l), urea (1.04 mmol/l), potas›
sium (0.30 mmol/l), and urate (42.0 ×6d mol/l) in the
group of patients treated with the combination
treatment. In three patients, a significant increase in
serum creatinine concentration was reported (two
patients on candesartan, one on the combination), but
these changes either resolved with continued treat›
ment or were of only modest nature and did not
require clinical intervention.
We observed no significant changes in mean creati›
nine clearance over 12 weeks in any of the treatment
groups. Creatinine clearance was slightly decreased
over 24 weeks in the groups treated with lisinopril
(adjusted mean decrease 0.0835 ml/sec, P = 0.04) and
the combination treatment (0.0735 ml/sec, P = 0.05)
but was not affected in the group treated with
candesartan.
Discussion
We can confirm that dual blockade of the renin›
angiotensisn system, both at the level of ACE and at the
level of the AII receptor, is associated with more effec›
tive reduction in blood pressure than observed with a
single agent and that this observation extends to
patients with diabetes. We cannot, however, determine
from the present study if these further effects on
urinary albumin excretion relate to more effective
reduction in blood pressure or to more complete
blockade of the renin›angiotensin system. Our results
provide additional evidence for a role for agents which
interrupt the renin›angiotensin system in conferring
renoprotective effects in patients with incipient
diabetic nephropathy.
Our results are consistent with experimental data
that emphasise the central role of interruption of the
renin›angiotensin system in mediating the renoprotec›
tive effects of ACE inhibitors.13 We cannot exclude that
the similarity in effects between ACE inhibitors and AII
receptor antagonists relates primarily to their similar
effects on blood pressure. Previous studies in patients
with hypertension, microalbuminuria, and type 2
diabetes, however, have suggested that part of the
effects on albuminuria of agents that interrupt the
renin›angiotensin system relate specifically to blockade
of this vasoactive hormone pathway.14 One of our main
findings was the ability of the combination of lisinopril
and candesartan to reduce blood pressure by about
8 mm Hg more than a single agent. Higher doses of a
single agent would probably not have achieved similar
effects on blood pressure.15 16 Effect is not related to
ACE genotypes.17–19
The role of dual blockade of the renin›angiotensin
system has been explored in other clinical contexts
with positive results.7 20 In a study of seven diabetic
patients, losartan was added to ACE inhibitor for seven
days.21 This had no effect on proteinuria, blood
pressure, or renal function. By contrast, positive effects
were observed in a trial of 4 weeks’ duration in normo›
tensive subjects with IgA nephropathy.22
Our study provides evidence of an important role
for combination therapy in patients with type 2
diabetes and incipient nephropathy as this treatment is
effective at reducing blood pressure, has a beneficial
effect on albuminuria, and is associated with an
excellent safety profile. The safety of such a
combination has recently been shown in a multicentre
study evaluating the effects of the combination of
valsartan and benazepril in patients with chronic renal
impairment.23
There was a tendency for glomerular filtration rate,
as assessed by the Cockroft›Gault formula, to decline
with ACE inhibition but not with AII receptor antago›
nism. It has been previously suggested that ACE
inhibitors may have different acute effects on renal
haemodynamics to AII antagonists and that this may
partly be bradykinin dependent.24 25
Recent guidelines for blood pressure targets in dia›
betic patients have emphasised the importance of
aggressive blood pressure reduction in diabetic
patients with evidence of renal disease.26–28 Our results
show that dual blockade of the renin›angiotensin
system is particularly effective in decreasing blood
pressure in these patients, and support this new and
potentially highly beneficial therapeutic approach for
the prevention of diabetic renal and vascular
disease.29 30
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Renal function—and how to assess it
The gold standard test for assessing renal function is
the glomerular filtration rate.1 Measuring this rate is a
laborious process but is most useful for assessing renal
function in patients whose serum creatinine concentra›
tion is at the upper limit of normal or in patients who
develop early renal impairment secondary to treat›
ment with non›steroidal anti›inflammatory drugs,
lithium, or angiotensin converting enzyme inhibitors.
The normal range is 80›120 ml/min.
A useful and practical surrogate marker for the
glomerular filtration rate is creatinine clearance.
Creatinine clearance measures the ability of the
kidneys to clear creatinine from the circulation into the
urine over a period of 24 hours. This is a much more
accessible measure of renal function, but because the
serum creatinine concentration is influenced by muscle
mass and age (it increases with muscle bulk and
decreases with age), creatinine clearance rates must be
interpreted for the individual patient. Body builders
have a tendency for high creatinine concentrations
while frail elderly women may have misleadlingly low
concentrations.
Most clinicians use serum creatinine concentrations
as the most practical measure of renal function. Normal
creatinine concentrations can be obtained even when
the glomerular filtration rate has dropped by 50%, how›
ever, so it is fairly insensitive as an indicator of early renal
insufficiency. Once serum creatinine concentrations are
abnormal it can be assumed that there is measurable
renal impairment (that is, more than half the filtering
capacity of the kidneys has been lost).
Measuring the blood urea concentration alone also
has limitations because it is influenced by protein
metabolism, the state of dehydration, and the use of ster›
oids, in addition to renal function. Thus patients with
renal impairment can have relatively normal blood urea
concentrations if they are grossly malnourished and not
eating.
The Cockroft›Gault formula (mentioned in the
paper) is a way of calculating the glomerular filtration
rate without undertaking a 24 hour urine collection.
The formula factors in age and body mass together
with serum creatinine concentrations in an attempt to
standardise the serum results and to be able to
compare one person’s renal function with another. It
tends to be used more in research settings than in rou›
tine clinical practice as a way of improving the quality
of data on renal function.
Abi Berger Science editor, BMJ
1 Cameron J, Greger R. Renal function and testing of function. In: Davison
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Endpiece
Youth, day, old age and night
Youth, large, lusty, loving—youth full of grace, force,
fascination,
Do you know that Old Age may come after you
with equal grace, force, fascination?
Day full›blown and splendid—day of the
immense sun, action, ambition, laughter,
The Night follows close with millions of suns,
and sleep and restoring darkness.
Walt Whitman, 1881
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